Hormonal therapy is one of the treatment options for prostate cancer patients.
There are many hormonal treatments modality to block the testosterone effect on prostate cancer cell proliferation. Degarelix is an innovative molecule able to antagonize the GnRH receptor with comparable oncological results to GnRH agonist, but with less side effects, avoiding the flare up phase, and better efficacy in LUTS relief. These characteristics of degarelix can impact on the clinical decision making to choose a therapy instead of another.
Written by:
Bertaccini A, Marchiori D. Are you the author?
Department of Urology, Alma Mater Studiorum University of Bologna, Sant'Orsola-Malpighi Hospital - Italy.
Reference: Urologia. 2012 Jul;79(3):197-9.
doi: 10.5301/RU.2012.9687
PubMed Abstract
PMID: 23032635
UroToday.com Prostate Cancer Section
